Formoterol, 24 μg bid, and serious asthma exacerbations: Similar rates compared with formoterol, 12 μg bid, with and without extra doses taken on demand, and placebo

Chest

Volumn 129, Issue 1, 2006, Pages 27-38

  Wolfe, James ^a   LaForce, Craig ^b   Friedman, Bruce ^c   Sokol, William ^d   Till, Denise ^e   Della Cioppa, Giovanni ^a,e   Van As, Andre ^f  

^a Allergy & Asthma Associates of Northern California   (United States)

^b North Carolina Clinical Research   (United States)

^c Allergy Asthma Bronchitis and Immunology Associates   (United States)

^d Health Research Institute   (United States)

^e NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adverse events; Aerolizer; Asthma; Bronchodilation; Exacerbations; Formoterol; High dose

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PLACEBO; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ETHANOLAMINE DERIVATIVE;

ADULT; ARTICLE; ASTHMA; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HOSPITALIZATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVOUSNESS; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SORE THROAT; SYMPTOMATOLOGY; SYSTEMIC THERAPY; TREMOR; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; AGED; CHILD; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SATISFACTION; QUESTIONNAIRE; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ASTHMA; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33144479545     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.1.27     Document Type: Article

References (21)

1. National Institutes of Health. National Heart, Lung, and Blood Institute. Expert panel report: guidelines for the diagnosis and management of asthma; update on selected topics 2002. NIH publication no. 02-5074, June 2003. Available at: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm/. Accessed August 23, 2004
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NIH publication 02-3659 issued January 1995, updated 2002, 2003. Available at: www.ginasthma.com/. Accessed December 20, 2005
3. Schermer TR, Hoff WJ, Greefhorst AP, et al. Profiles of measured and perceived bronchodilation: a placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma. Pulm Pharmacol Ther 2004; 17:205-212
4. Dahl R, Creemers JP, Van Noord J, et al. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma. Respiration 2004; 71:126-133
5. Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax 1992; 47:30-33
6. van Noord JA, Smeets JJ, Raaijmakers JA, et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9:1684-1688
7. Wallin A, Sandstrom T, Rosenhall L, et al. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax 1993; 48:611-614
8. Wegener T, Hedenstrom H, Melander B. Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 1992; 102:535-538
9. Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991; 42:115-137
10. Bartow RA, Brogden RN. Formoterol: an update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998; 55:303-322;
11. erratum in: Drugs 1998; 55:517
12. Bensch G, Lapidus RJ, Levine BE, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001; 86:19-27
13. Bensch G, Berger WE, Blokhin BM, et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 2002; 89:180-190
14. Pleskow W, LaForce CF, Yegen U, et al. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. J Asthma 2003; 40:505-514
15. Mitchell C, Jenkins C, Scicchitano R, et al. Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulm Pharmacol Ther 2003; 16:299-306
16. Pearlman DS, Kottakis J, Till D, et al. Formoterol delivered via a dry powder inhaler (Aerolizer): results from long-term clinical trials in children. Curr Med Res Opin 2002; 18:445-455
17. Nelson HS, Weiss ST, Bleecker ER, et al, and the SMART Study Group. The Salmeterol Multicenter Asthma Research Trial (SMART): a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26
18. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124:70-74
19. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Pulmonary-Allergy Drugs Advisory Committee (PADAC), 13 July 2005. Available at: www.fda.gov/ohrms/dockets/ac/05/slides/2005-4148S1_04_02-Novartis- Safety.ppt#364,10, Primary Outcome Data for Study 2307 (slide 10), accessed September 1, 2005.
20. Abramson MJ, Walters J, Walters EH. Adverse effects of beta-agonists: are they clinically relevant? Am J Respir Med 2003; 2:287-297
21. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Approval package. Foradil (Formolterol Fumarate Inhalation) Aerolizer. Available at: www.fda.gov/cder/foi/nda/2001/20831_Foradil.htm, accessed September 1, 2005